
SNY Valuation
Sanofi SA
- Overview
- Forecast
- Valuation
- Earnings
SNY Relative Valuation
SNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, SNY is overvalued; if below, it's undervalued.
Historical Valuation
Sanofi SA (SNY) is now in the Fair zone, suggesting that its current forward PE ratio of 10.00 is considered Fairly compared with the five-year average of 10.94. The fair price of Sanofi SA (SNY) is between 45.11 to 64.53 according to relative valuation methord.
Relative Value
Fair Zone
45.11-64.53
Current Price:46.18
Fair
10.00
PE
1Y
3Y
5Y
Trailing
Forward
7.69
EV/EBITDA
Sanofi SA. (SNY) has a current EV/EBITDA of 7.69. The 5-year average EV/EBITDA is 9.21. The thresholds are as follows: Strongly Undervalued below 7.93, Undervalued between 7.93 and 8.57, Fairly Valued between 9.85 and 8.57, Overvalued between 9.85 and 10.50, and Strongly Overvalued above 10.50. The current Forward EV/EBITDA of 7.69 falls within the Strongly Undervalued range.
8.42
EV/EBIT
Sanofi SA. (SNY) has a current EV/EBIT of 8.42. The 5-year average EV/EBIT is 10.27. The thresholds are as follows: Strongly Undervalued below 8.77, Undervalued between 8.77 and 9.52, Fairly Valued between 11.02 and 9.52, Overvalued between 11.02 and 11.78, and Strongly Overvalued above 11.78. The current Forward EV/EBIT of 8.42 falls within the Strongly Undervalued range.
2.16
PS
Sanofi SA. (SNY) has a current PS of 2.16. The 5-year average PS is 2.62. The thresholds are as follows: Strongly Undervalued below 2.18, Undervalued between 2.18 and 2.40, Fairly Valued between 2.84 and 2.40, Overvalued between 2.84 and 3.06, and Strongly Overvalued above 3.06. The current Forward PS of 2.16 falls within the Strongly Undervalued range.
9.63
P/OCF
Sanofi SA. (SNY) has a current P/OCF of 9.63. The 5-year average P/OCF is 10.95. The thresholds are as follows: Strongly Undervalued below 9.07, Undervalued between 9.07 and 10.01, Fairly Valued between 11.88 and 10.01, Overvalued between 11.88 and 12.82, and Strongly Overvalued above 12.82. The current Forward P/OCF of 9.63 falls within the Undervalued range.
13.25
P/FCF
Sanofi SA. (SNY) has a current P/FCF of 13.25. The 5-year average P/FCF is 13.91. The thresholds are as follows: Strongly Undervalued below 11.12, Undervalued between 11.12 and 12.52, Fairly Valued between 15.30 and 12.52, Overvalued between 15.30 and 16.69, and Strongly Overvalued above 16.69. The current Forward P/FCF of 13.25 falls within the Historic Trend Line -Fairly Valued range.
Sanofi SA (SNY) has a current Price-to-Book (P/B) ratio of 1.43. Compared to its 3-year average P/B ratio of 0.98 , the current P/B ratio is approximately 45.16% higher. Relative to its 5-year average P/B ratio of 0.93, the current P/B ratio is about 53.56% higher. Sanofi SA (SNY) has a Forward Free Cash Flow (FCF) yield of approximately 9.51%. Compared to its 3-year average FCF yield of 3.22%, the current FCF yield is approximately 195.72% lower. Relative to its 5-year average FCF yield of 3.28% , the current FCF yield is about 190.52% lower.
1.43
P/B
Median3y
0.98
Median5y
0.93
9.51
FCF Yield
Median3y
3.22
Median5y
3.28
Competitors Valuation Multiple
The average P/S ratio for SNY's competitors is 4.06, providing a benchmark for relative valuation. Sanofi SA Corp (SNY) exhibits a P/S ratio of 2.16, which is -46.68% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
1Y
3Y
5Y
Market capitalization of SNY increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of SNY in the past 1 year is driven by Unknown.
People Also Watch

KKR
KKR & Co Inc
144.560
USD
+1.33%

TTE
TotalEnergies SE
60.200
USD
-0.13%

PANW
Palo Alto Networks Inc
172.890
USD
+2.25%

ETN
Eaton Corporation PLC
358.160
USD
+0.48%

BSX
Boston Scientific Corp
102.950
USD
-1.79%

C
Citigroup Inc
92.230
USD
+0.78%

SONY
Sony Group Corp
24.920
USD
+1.59%

COP
ConocoPhillips
93.110
USD
-0.10%

UBER
Uber Technologies Inc
89.220
USD
-0.19%

BHP
BHP Group Ltd
51.540
USD
+0.80%
FAQ

Is Sanofi SA (SNY) currently overvalued or undervalued?
Sanofi SA (SNY) is now in the Fair zone, suggesting that its current forward PE ratio of 10.00 is considered Fairly compared with the five-year average of 10.94. The fair price of Sanofi SA (SNY) is between 45.11 to 64.53 according to relative valuation methord.

What is Sanofi SA (SNY) fair value?

How does SNY's valuation metrics compare to the industry average?

What is the current P/B ratio for Sanofi SA (SNY) as of Aug 07 2025?

What is the current FCF Yield for Sanofi SA (SNY) as of Aug 07 2025?

What is the current Forward P/E ratio for Sanofi SA (SNY) as of Aug 07 2025?
